

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Doxecitine-doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484

Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
UCB Pharma (doxecitine	All Wales Inherited Metabolic Disease
doxribtimine)	Service Cardiff
Patient/carer groups	 All Wales Therapeutics and Toxicology Centre
Beacon	Allied Health Professionals Federation
Gene People	Board of Community Health Councils in
Genetic Alliance UK	Wales
Metabolic Support UK	British National Formulary
Muscular Dystrophy UK	Care Quality Commission
South Asian Health Foundation	Cell and Gene Therapy Catapult
Specialised Healthcare Alliance	Department of Health - Northern Ireland
The Lily Foundation	Healthcare Improvement Scotland
	Medicines and Healthcare products
	Regulatory Agency
Healthcare professional groups	National Association of Primary Care
Association of British Neurologists	National Pharmacy Association
Association of Genetic Nurses &	NHS Confederation
Counsellors	NHS Wales Joint Commissioning
Association of Paediatric Chartered Dhygiotherapiete	Committee
PhysiotherapistsBritish Inherited Metabolic Disorder	Scottish Medicines Consortium
Group	Welsh Government
British Myology Society	Possible comparator companies
British Paediatric Neurology	Possible comparator companiesNone
Association	140HC
British Society for Gene and Cell	Relevant research groups
Therapy	Cochrane Cystic Fibrosis & Genetic
British Society for Genetic Medicine	Disorders Group
Neonatal and Paediatric Pharmacists	Genomics England
Group	MRC Clinical Trials Unit
Royal College of General Practitioners	MRC Mitochondrial Biology Unit
Royal College of Nursing	National Institute for Health Research
Royal College of Paediatrics & Child	
Health	Associated Public Health groups
 Royal College of Pathologists 	Public Health Wales


Stakeholder list for the evaluation of doxecitine-doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine The Chartered Society of Physiotherapy UK Clinical Pharmacy Association United Kingdom National Screening Committee 	UK Health Security Agency
 Others Department of Health and Social Care Department of Paediatric Neurology, Manchester University NHS Foundation Trust Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust NHS England NHS Rare Mitochondrial Disorders Service (Newcastle Mitochondrial Service, University College London Hospital NHS Highly Specialised Service for Rare Mitochondrial Disorders & Oxford University Hospitals Rare Mitochondrial Disorders Service) The Charles Dent Metabolic Unit, University College London Hospital NHS Foundation Trust The Mark Holland Metabolic Unit, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust Willink Biochemical Genetics Unit, Manchester University NHS Foundation Trust 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:



Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.